Levy and colleagues [15] addressed the question of cancer risk reduction with GLP-1 receptor agonist use in adult patients with obesity in a large-scale cohort study using the TriNetX US Collaborative Network database (2013–2023). Here, GLP1R is linked to obesity disorder.